Spots Global Cancer Trial Database for cd20 positive
Every month we try and update this database with for cd20 positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04007029 | CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02219737 | CD20 Positive Recurrent Diffu... Refractory Diff... | Carboplatin Etoposide Ibrutinib Ifosfamide Laboratory Biom... Pharmacological... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT03946878 | Blastoid Varian... CCND1 Protein O... CD20 Positive CD5 Positive FCER2 Negative Pleomorphic Var... Recurrent Mantl... Refractory Mant... t(11;14)(q13;q3... | Acalabrutinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01880567 | CCND1 Positive CCND2 Positive CCND3 Positive CD20 Positive Mantle Cell Lym... Recurrent Mantl... Refractory Mant... | Ibrutinib Laboratory Biom... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma | NCT02532257 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... CD20 Positive Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... | Ibrutinib Laboratory Biom... Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant | NCT00439556 | CD20 Positive Hematopoietic a... Lymphocytic Neo... Lymphoma | Allogeneic Hema... Anti-Thymocyte ... Bortezomib Carmustine Cytarabine Etoposide Filgrastim Melphalan Methotrexate Rituximab Tacrolimus | - 70 Years | M.D. Anderson Cancer Center | |
| Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant | NCT00880815 | CD20 Positive Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Recurrent Diffu... T-Cell Non-Hodg... | Allogeneic Hema... Anti-Thymocyte ... Bendamustine Filgrastim Fludarabine Methotrexate Rituximab Tacrolimus | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia | NCT00742144 | Leukaemia, Lymp... | ofatumumab | 20 Years - 79 Years | GlaxoSmithKline | |
| Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma | NCT01729806 | CD20 Positive Recurrent B-Cel... Refractory B-Ce... | Ipilimumab Laboratory Biom... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma | NCT01729806 | CD20 Positive Recurrent B-Cel... Refractory B-Ce... | Ipilimumab Laboratory Biom... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02219737 | CD20 Positive Recurrent Diffu... Refractory Diff... | Carboplatin Etoposide Ibrutinib Ifosfamide Laboratory Biom... Pharmacological... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | NCT03267433 | CD20 Positive Mantle Cell Lym... | Autologous Hema... Laboratory Biom... Rituximab | 18 Years - 70 Years | Eastern Cooperative Oncology Group | |
| Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | NCT01363128 | Acute Lymphobla... Adult Acute Lym... Burkitt Leukemi... Burkitt Lymphom... CD20 Positive Childhood Acute... Lymphoblastic L... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul... | - | M.D. Anderson Cancer Center | |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04007029 | CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia | NCT00742144 | Leukaemia, Lymp... | ofatumumab | 20 Years - 79 Years | GlaxoSmithKline | |
| Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | NCT03267433 | CD20 Positive Mantle Cell Lym... | Autologous Hema... Laboratory Biom... Rituximab | 18 Years - 70 Years | Eastern Cooperative Oncology Group | |
| Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01880567 | CCND1 Positive CCND2 Positive CCND3 Positive CD20 Positive Mantle Cell Lym... Recurrent Mantl... Refractory Mant... | Ibrutinib Laboratory Biom... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma | NCT01959698 | CD20 Positive Recurrent Diffu... Refractory Diff... Stage I Diffuse... Stage II Diffus... Stage III Diffu... Stage IV Diffus... | Carboplatin Carfilzomib Etoposide Ifosfamide Laboratory Biom... Pharmacological... Rituximab | 18 Years - 75 Years | Roswell Park Cancer Institute | |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04007029 | CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
